Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Diseases

Taiga Otsuka⁴  Shunya Nakashita⁴  Kimihiko Yanagita⁷  Keisuke Ario²  Hiroaki Kawasoe⁵  Seiji Kawazoe⁶  Yuichiro Eguchi³  Toshihiko Mizuta⁴  rib-type="author">the Saga Liver Cancer Study Group†contrib-type="author">the Saga Liver Cancer Study Group†<¹ 

[1]Department of Internal Medicine, Gastroenterology Division, NHO Ureshino Medical Center, 2436 Shimojuku-hei Ureshino-machi, Ureshino 843-0393, Japan

[2] E-Mail:

[3]Liver center, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan

[4] E-Mail:

[5]Department of Internal Medicine, Hepatology Division, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan

[6] E-Mails:

[7]Department of Internal Medicine, Karatsu Red Cross Hospital, 1-5-1 Futago, Karatsu 847-8588, Japan

[8] E-Mail:

[9]Department of Hepatobiliary and Pancreatology, Saga-Ken Medical Centre Koseikan, 400 Nakabaru, Kase-machi, Saga 840-8571, Japan

[10] E-Mail:

[11]Department of Internal Medicine, Saiseikai Karatsu Hospital, 817 Motohata-machi, Karatsu 847-0852, Japan

[12] E-Mail:

关键词: beyond progression;    progressive disease;    scoring system;    post-progression survival;   

DOI  :  10.3390/diseases3020068

来源: mdpi

【 摘 要 】

Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated from the date of the first rPD until the date of death or the last follow-up. Using Cox model analysis of the 76 patients who experienced first rPD, we identified the Child-Pugh class, Eastern Cooperative Oncology Group performance status, the best antitumor response during treatment (using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1) and α-fetoprotein levels as independent factors affecting PPS. When these factors were used to define scores ranging from zero to five with a cutoff value of two, PPS of patients who received best supportive care (BSC) after rPD was not statistically significantly different from that of patients who received post-rPD therapy with scores ≥2 (p = 0.220). In contrast, the PPS for the post-rPD therapy group was significantly longer compared with the BSC patients with scores <2 (p < 0.001). Patients who scored ≥2 at their first rPD were judged cPD and as candidates for BSC.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.